REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | 21 |
SOURCE | Rabbit |
Product Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
From sample preparation to detection, the reagents you need for your Western Blot are now in one convenient kit: #12957 Western Blotting Application Solutions Kit
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Loading of prestained molecular weight markers (#59329, 10 µl/lane) to verify electrotransfer and biotinylated protein ladder (#7727, 10 µl/lane) to determine molecular weights are recommended.
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 10
Human
Mouse, Rat
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly81 of human Bmf protein. Antibodies are purified by protein A and peptide affinity chromatography.
The BH3-only proteins are a group of pro-apoptotic proteins of the Bcl-2 family that share the conserved BH3 domain but lack BH1, BH2, and BH4 (1). This short BH3 domain is essential for interaction with pro-survival members of the Bcl-2 family and allows for their pro-apoptotic activity. A large number of BH3-only proteins have been identified in mammals, including Bmf, Bad, Bik, Bid, Bim, Hrk, Noxa, and Puma. Many of these proteins appear to display distinct roles in apoptosis through tissue-specific expression. Bmf (Bcl-2-modifying factor) was originally identified in a yeast two-hybrid screen using the pro-survival protein Mcl-1 as bait (2). Bmf appears to be widely expressed, with bmf mRNA observed in cell lines of B- and T-lymphoid, myeloid, or fibroblastoid origin and in mouse embryos at all developmental stages. Bmf protein is seen most abundantly in pancreas, liver, kidney, and hematopoietic tissues (2, 3). Bmf interacts with several pro-survival Bcl-2 proteins including Mcl-1, Bcl-2, Bcl-xL, and Bcl-w, and the interaction depends on the BH3 domain (2). Like Bim, Bmf has been reported to bind to cytoskeletal structures. Bmf is normally sequestered to myosin V motors through association with dynein light chain 2 (DLC2). Certain damage signals, such as the detachment of adherent cell lines from their substratum (anoikis), triggers the release of Bmf and subsequent binding to the pro-survival Bcl-2 proteins (2).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.